US pharma giant Eli Lilly chooses Telangana to invest over USD 1 billion
US pharma giant Eli Lilly will invest USD 1 billion in Telangana to expand its manufacturing and global medicine supply capacity. The company chose Hyderabad for its skilled workforce, infrastructure and government support after inaugurating its Global Capability Centre in August
Hyderabad: Telangana has secured an investment of USD 1 billion from US pharma major Eli Lilly to expand its manufacturing and global medicine supply capacity in Hyderabad.
The announcement was made after a delegation from the company met Chief Minister A Revanth Reddy and Industries Minister D Sridhar Babu at the Integrated Command Control Centre here on Monday.
The company inaugurated its Global Capability Centre (GCC) in Hyderabad in August this year. Despite strong interest from several other states, Eli Lilly chose Telangana owing to the favourable ecosystem, availability of skilled manpower, infrastructure, and proactive government support, according to an official press release.
The USD 1 billion investment by Eli Lilly reflects the company’s interest in Telangana beyond its GCC operations and focuses on developing new medicines to treat diabetes and obesity, Alzheimer’s disease, cancer and autoimmune conditions.
With the setting up of the new facilities, Eli Lilly is set to manufacture in Telangana and supply globally.
Sridhar Babu said Lilly’s expansion in Hyderabad was a testament to Telangana’s dynamic industrial landscape and its growing prominence in advanced healthcare manufacturing.
